Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Multi Center Study of BGB324 in Combination With Pembrolizumab in Patients With Previously Treated Advanced Adenocarcinoma of the Lung

NCT03184571 is registered in ClinicalTrials.gov with BerGenBio ASA as lead sponsor.

NCT NCT03184571
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03184571 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Multi Center Study of BGB324 in Combination With Pembrolizumab in Patients With Previously Treated Advanced Adenocarcinoma of the Lung
Lead sponsor
BerGenBio ASA
Phase
Phase 2
Overall status
Completed
Start date
October 2, 2017
Completion date
October 27, 2022
Enrollment
99 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of lung, lung cancer metastatic, nsclc stage iv